Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OGX-011

Known as: ISIS 112989 
A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Thionucleotidesclusterin antisense oligonucleotide

Narrower (1)

custirsen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel…
BACKGROUND Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration… Expand
Is this relevant?
2012
2012
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
PURPOSE Clusterin (CLU), an antiapoptotic, stress-associated protein, confers resistance to therapy when overexpressed. This… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after…
PURPOSE Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Small-molecule inhibitors of Hsp90 show promise in the treatment of castrate-resistant prostate cancer (CRPC); however, these… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
PURPOSE To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.
PURPOSE Clusterin is an antiapoptotic protein activated in response to cellular stress. OGX-011 is a second-generation antisense… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
OBJECTIVES To characterize changes in secretory clusterin (sCLU) expression in prostate cancer cells after treatment with… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
PURPOSE Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
The pharmacokinetics of a 2'-O-(2-methoxyethyl)-modified oligonucleotide, ISIS 301012 [targeting human apolipoprotein B-100 (apoB… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
BACKGROUND Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE